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The charged multivesicular body protein 2B gene (CHMP2B) was recently associated with frontotemporal
lobar degeneration (FTLD) linked to chromosome 3 in a Danish FTLD family (FTD-3). In this family, a mutation
in the acceptor splice site of exon 6 produced two aberrant transcripts predicting two C-truncated CHMP2B
proteins due to a read through of intron 5 (p.Met178ValfsX2) and a cryptic splicing event within exon 6
(p.Met178LeufsX30). Extensive mutation analysis of CHMP2B in Belgian patients (N5146) identified one non-
sense mutation in exon 5 (c.493C>T) in a familial FTLD patient, predicting a C-truncated protein p.Gln165X
analogous to the Danish mutant proteins. Overexpression of Belgian p.Gln165X in human neuroblastoma
SK-N-SH cells showed the formation of large, aberrant endosomal structures that were highly similar to
those observed for Danish p.Met178ValfsX2. Together, these data suggest that C-truncating mutations in
CHMP2B might underlie the pathogenic mechanism in FTLD by disturbing endosome function. We also
describe a missense mutation in exon 5 of CHMP2B (p.Asn143Ser) in a familial patient with cortical basal
degeneration. However, the pathogenic character of this mutation remains elusive.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) represents a clini-
cally and pathologically heterogeneous group of primary neu-
rodegenerative dementias with predominant frontal and/or
temporal lobe symptoms. It can present as frontotemporal
dementia (FTD), which comprises the major group. In FTD
patients, behaviour and personality changes are predominant.
Other patients present primarily with language dysfunction,
with behavioural changes occurring later in the disease
course. This group can be further classified into progressive
non-fluent aphasia (PNFA) where patients experience difficul-
ties in language expression and semantic dementia (SD) which
is characterized by problems in word comprehension and
naming (1,2). In addition, signs of parkinsonism can develop
during the course of the disease, and in some patients,
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FTLD concurs with motor neuron disease. Like FTLD, pro-
gressive supranuclear palsy (PSP) and corticobasal degener-
ation (CBD) are focal neurodegenerative disorders with
frequent personality changes, speech disturbances and parkin-
sonism. Multiple studies have demonstrated that there exists a
significant clinical and pathological overlap between FTLD,
PSP and CBD. Patients presenting clinically as CBD or PSP
have been described with FTLD with tau as well as ubiquitin
positive pathology (3–5). Conversely, PSP and CBD pathol-
ogies can underlie clinical symptoms of FTLD (6–8). The
degree of overlap between CBD, PSP and FTLD suggests
that these relatively rare conditions might be part of a more
common spectrum of neurodegenerative disorders.
The majority of FTLD families have been linked to chromo-
somes 17q21 and a wide range of mutations have been ident-
ified in the microtubule associated protein tau gene (MAPT)
(9) and the progranulin gene (PGRN) (10,11) (AD&FTD
Mutation database: http://www.molgen.ua.ac.be/FTDmuta-
tions). In a large Danish kindred, however, dominant FTLD
was linked to the pericentromeric region of chromosome 3
(FTD-3) (12). Ten years later, a mutation was identified in
the gene coding for the charged multivesicular body (MVB)
protein 2B—also known as chromatin-modifying protein
2B—(CHMP2B) located at 3p11.2, that segregated with
FTLD in this family (13).
CHMP2B encodes a component of the heteromeric
ESCRT-III complex (Endosomal Sorting Complex Required
for Transport III). In eukaryotic cells, the sorting of cell
surface receptors for recycling to the plasma membrane or
the Golgi complex, or for degradation by the lysosome is
mediated by the MVB pathway (14). MVBs are late endoso-
mal structures which fuse with the lysosome and are formed
by invagination and budding of vesicles from the limiting
membrane of endosomes into the endosomal lumen. This
process requires the transient formation of three ESCRT com-
plexes I–III (14,15). These multisubunit protein complexes
are recruited from the cytoplasm and were first identified in
yeast as class E Vps (vacuolar protein sorting) proteins. Del-
etion or loss of function of each of these proteins has been
shown to induce accumulation of transmembrane proteins in
large aberrant structures on the limiting membrane of enlarged
dysmorphic endosomes, referred to as class E compartments
(14,16). Yeast Vps proteins have one or more human ortholo-
gues, pointing to a greater complexity of the MVB pathway in
mammals. CHMP2B is one of the two human orthologues of
the yeast Vps2 protein and forms a component of the
ESCRT-III complex. The six ESCRT-III proteins in yeast
have at least 10 apparent human homologues called the
charged MVB proteins or CHMP proteins (17). CHMP pro-
teins cycle between a monomeric state in the cytosol and an
oligomerized state in large ESCRT-III complexes on the limit-
ing membrane of the endosome (14,18–20). ESCRT-III func-
tions in the concentration of ubiquitinated endosomal cargo for
invagination into the MVB intralumenal vesicles (14,18).
After proteins are sorted, ESCRT-III recruits an AAA-ATPase
(VPS4) for active dissociation of the membrane-bound
complex and recycling of its components into the cytosol for
further rounds of MVB sorting (14,18,21). CHMP proteins
are conserved throughout eukaryotic evolution and show
strong structural homology. They are small 200–250
amino acid soluble coiled-coil proteins with characteristic
basic N-terminal and acidic C-terminal halves (18).
CHMP2B is a 213-amino-acid protein that contains, next to
the two coiled-coil domains (residues 1–50 and 120–150), a
large predicted Snf-7 domain (residues 16–178). It is
expressed in all major regions of the brain and in all neuronal
populations, especially in hippocampus, frontal and temporal
lobes and cerebellum (13).
The Danish CHMP2B G-to-C mutation was found in the
acceptor splice site of exon 6 and was shown to produce
two abundant splice variants in brain predicting proteins
with altered C-terminal sequences (13) (Fig. 1C). In the first
transcript referred to as CHMP2BIntron5, read-through of
intron 5 caused a deletion of 36 amino acids creating a
C-altered tail of one Val-residue (p.Met178ValfsX2). In the
second mutant transcript CHMP2BD10, the use of a cryptic
splice site within exon 6 deleted 10 bp and produced a
C-truncated protein with 29 residues of nonsense sequence
(p.Met178LeufsX30). Further, overexpression of these
mutant transcripts in rat PC12 cells caused an aberrant pheno-
type characterized by the accumulation of mutant CHMP2B
on the outer membrane of enlarged, dysmorphic endosomes,
similar to the observations made in yeast Vps mutants (13).
In addition to the Danish splice site mutation, a missense
mutation (p.Asp148Tyr) was reported in an SD patient
without clear family history of neurodegenerative disease
(13). However, altogether CHMP2B appeared to be a rare
cause of FTLD since several large FTLD patient series
failed to detect any CHMP2B mutations (22–24).
In the present study, we performed an extensive exonic
mutation analysis of CHMP2B in a Belgian patient series com-
prising 134 unrelated FTLD patients. Considering the clinico-
pathological overlap between FTLD, CBD and PSP, we also
included seven patients with a clinical diagnosis of CBD and
five patients diagnosed with PSP. In a familial FTLD
patient, we identified a novel nonsense mutation in exon 5
resulting in a stably expressed mutant transcript coding for a
C-truncating protein (p.Gln165X). Overexpression studies
showed a similar cellular effect for the Belgian and Danish
C-truncated proteins with both leading to an aberrant endoso-
mal phenotype. Further, we observed one missense mutation
in exon 5 (p.Asn143Ser) in a familial CBD patient.
RESULTS
CHMP2B genetic studies
In a Belgian series of 146 patients who had previously been
screened for mutations in the genes MAPT, PGRN, PSEN1
and VCP, we identified two mutations located within
CHMP2B exon 5. A C-to-T transition (c.493C.T; FTLD
patient DR157.1) at 39 bp near the 30 end of exon 5
(Fig. 1A and B), predicted a stop codon resulting in a
C-truncated protein of 165 amino acids, p.Gln165X
(Fig. 1C). RT–PCR analysis of CHMP2B complementary
DNA (cDNA) of the patient’s lymphoblasts confirmed the pre-
sence of mutant transcript (Fig. 1B). A second mutation
A-to-G was identified near the 50 end of exon 5 (c.428A.G;
CBD patient DR70.1) (Fig. 1A and B), predicting an amino
acid substitution, p.Asn143Ser. Asn143 is a highly conserved
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amino acid residue from human to Drosophila and is located
in the conserved Snf7 domain (residues 16–178) as well as
in the second coiled-coil domain (residues 120–150) of
CHMP2B. The mutation is located near the splice acceptor
site of exon 5, however, sequencing of lymphoblast
CHMP2B cDNA showed only the wild-type and missense
transcripts excluding the formation of aberrantly spliced tran-
scripts (Fig. 1B). Both exon 5 mutations, c.493C.T and
c.428A.G, were absent in 459 Belgian control individuals.
In the FTLD family DR157, we examined the presence of
the mutation in available family members and performed hap-
lotype segregation using a set of nine microsatellite markers
(Fig. 2). None of the four at-risk individuals carried the
p.Gln165X mutation or the risk haplotype. Both sisters of
the index patient, aged 81 and 61, were without symptoms
of FTLD. In the CBD family DR70, only one healthy at-risk
individual was available for testing. This person carried the
p.Asn143Ser mutation but was still below the onset age of
the index patient (pedigree not shown for reasons of confiden-
tiality).
Clinical phenotypes
The index patient of the FTLD family DR157 who carried the
p.Gln165X mutation showed first signs of the disease at the
age of 58. Dysgraphia was the earliest symptom which
progressively deteriorated. Her family complained that she
often repeated the same thing. There also was loss of
decorum with mild disinhibition. Two years after disease
onset, neurological testing showed a light disorientation in
space and time. There was severe dysgraphia with dysortho-
graphia and grammatical errors. The patient confabulated.
Mild dyslexia, dyspraxia and severe dyscalculia were
observed; however, delayed recall was preserved. The
patient scored 21/30 on mini mental state examination
(MMSE). Computer-assisted tomography (CT) scan showed
a mild frontal cortical atrophy. At the age of 64, the patient
was clearly disoriented in space and time, her handwriting
had become unreadable and the dyslexia had severely wor-
sened. She exhibited logorrhoea and perseverated. Dyspraxia
had increased, and delayed recall was now clearly impaired.
Her MMSE score had dropped to 7/30. The CT scan revealed
generalized cortical atrophy, somewhat more pronounced at
the temporal medial gyrus both left and right. Her mother
and maternal aunt suffered from dementia and died without
autopsy (Fig. 2). According to family informants, the brother
of her grandmother and his son were also affected, but
medical records could not be obtained.
The index patient in family DR70 who carried the missense
mutation p.Asn143Ser was diagnosed with CBD. Symptoms
started 2 years prior to clinical diagnosis at 73 years with
progressive deterioration of memory, disorientation in space
and time, behavioural problems, global aphasia with severe
anomia and speech production problems, tendency to
mutism, acalculia, dressing dyspraxia and important bradypsy-
chisme. At diagnosis, she had an MMSE score of 11/30.
Figure 1. CHMP2B C-truncating mutations cause FTLD linked to chromosome 3. (A) Schematic representation of the CHMP2B gene. (B) Sequence traces of
CHMP2B mutations identified in a Belgian FTLD patient (c.493C.T; DR157.1) and a CBD patient (c.428A.G; DR70.1) on gDNA and on cDNA prepared
from lymphoblasts of patient DR157.1 and an asymptomatic at-risk individual DR70.2. Numbering under nucleotides indicates the relative position in exon
5. (C) Schematic representation of the CHMP2B wild-type protein and C-truncated proteins encoded by the Belgian nonsense mutation p.Gln165X and the
Danish splice site mutations p.Met178ValfsX2 and p.Met178LeufsX30. For the Danish C-truncated transcripts, altered amino acid sequences are given.
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Parallel with the cognitive decline, she developed an extra-
pyramidal syndrome presenting with resting tremor of the
right foot and later in the disease course pronounced global
rigidity and cogwheel phenomenon, hypomimia and hypokine-
sia, reduced arm swing and shuffling gait. Further, finger
agnosia, vertical gaze palsy and vivid symmetrical tendon
reflexes were reported. Structural imaging failed because the
patient could not lie still. Single photon emission computed
tomography (SPECT) scan showed diastasis of frontal
cortical activity. The patient died at 80 years without
autopsy. Genealogical investigation revealed a maternal aunt
with dementia, whereas her mother died early at the age of 54.
Functional studies
We compared the subcellular localization of wild-type CHMP2B
(CHMP2BWildtype), Belgian p.Gln165X (CHMP2BQ165X), and
the Danish p.Met178ValfsX2 (CHMP2BIntron5) proteins in
human neuroblastoma SK-N-SH cells that were transiently trans-
fected with the respective N-terminal c-myc tagged expression
Figure 2. Pedigree of the Belgian FTLD family with the CHMP2B p.Gln165X mutation. Information on affection status, current age or age at death for deceased
relatives and age at onset in patients are given when available. Open symbols represent unaffected individuals, filled symbols patients and half-filled symbols
individuals who were affected according to family informants. An arrowhead identifies the index patient. The pedigree was anonymized to protect privacy of the
family. The numbers within each diamond represent unaffected at-risk individuals. Segregation data are given for c.493C.T, p.Gln165X and nine flanking
microsatellite markers. The black bar represents the risk haplotype. When the phase could not be determined, genotypes are given between parentheses.
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constructs. Twenty-four hours post-transfection, localization of
CHMP2B (visualized with an anti-c-myc antibody) showed
large vesicular structures in the cells transfected with
CHMP2BIntron5 (Fig. 3B) and CHMP2BQ165X (Fig. 3C and D).
This was in contrast to CHMP2BWildtype (Fig. 3A), which
showed a generally diffuse pattern of staining. Occasional ves-
icular structures that were much smaller than those seen with
the mutant constructs were observed, possibly due to the
expected transient association of CHMP2B with endosomes.
We also noted that many more cells per well expressed
CHMP2BWildtype than the mutant constructs. This may be due
to faster degradation or less efficient translation of the mutant
proteins. This difference was confirmed by western blotting,
which showed a greater level of CHMP2BWildtype than
CHMP2BIntron5 and CHMP2BQ165X in cell lysates from equival-
ent transfections (Supplementary Material, Fig. S1).
CHMP2BQ165X was also observed in the nucleus (Fig. 3C and
D). This localization differed from CHMP2BIntron5 (Fig. 3B),
which was generally excluded from the nucleus. These staining
patterns were also observed at 48 h post-transfection as well as
in a second cell line, SH-SY-5Y (Supplementary Material,
Fig. S2). Blind counts of the localization of overexpressed
CHMP2B proteins confirmed that the predominant cellular phe-
notype for CHMP2BIntron5 and CHMP2BQ165X were large ves-
icular structures, whereas CHMP2BWildtype had predominantly
diffuse staining. For CHMP2BQ165X, the vesicular staining
appeared either on a background of diffuse cytoplasmic and
nuclear staining (32% of transfected cells) or more commonly
with only nuclear and no cytoplasmic staining (46% of trans-
fected cells) (Fig. 3C and D).
Immunostaining with the endosomal marker CD63 showed
partial co-localization with CHMP2B-positive vesicular struc-
tures (Fig. 4), indicating that at least some of the vesicular
structures are aberrant endosomal structures that may be ana-
logous to the class E structures observed with ESCRT protein
mutants in yeast (18). Co-localization was confirmed with a
second late endosomal marker, LAMP-1 (data not shown).
DISCUSSION
To date, the Danish FTLD family (FTD-3) remains the only
FTLD family linked to the pericentromeric region of chromo-
some 3 (13), complicating the identification of the underlying
disease gene. Candidate gene sequencing identified a splice
site mutation in CHMP2B segregating with the disease in
the FTD-3 family, that produced two frameshift transcripts
predicting the C-truncated proteins p.Met178ValfsX2 and
p.Met178LeufsX30 (13), and excluded causal mutations in
all other known genes in the candidate region (25). A potential
pathogenic mechanism for the C-truncation of CHMP2B was
suggested by the observation of an aberrant cellular endosomal
phenotype upon overexpression of p.Met178ValfsX2 in PC12
cells (13). However, numerous mutation screening studies in
series of sporadic and familial FTLD patients failed to identify
additional pathogenic CHMP2B mutations (22–24), indicating
that, if CHMP2B is the chromosome 3 gene, its genetic contri-
bution to FTLD has to be very low.
In a Belgian patient series (N¼146), we identified a novel
nonsense mutation in a familial FTLD patient located in
penultimate exon 5 of CHMP2B. The index patient developed
the first signs of FTLD at the age of 58 and had a family
history of dementia indicative of an autosomal dominant
mode of inheritance. Only four healthy at-risk individuals
(age range 44–81 years) were available for genetic studies,
and segregation analysis revealed neither the mutation nor
the risk haplotype. Notably, the oldest sister died without
signs of disease at the age of 81, more than 20 years later
than the disease onset in the proband. Unfortunately, no path-
ology data were yet available to support the clinical diagnosis
of FTLD in this family since the index patient is still alive, and
patients from previous generations died without autopsy.
Consistent with the Danish CHMP2B frameshift mutations
(p.Met178ValfsX2 and p.Met178LeufsX30), the Belgian non-
sense mutation predicted the formation of a C-truncated
protein p.Gln165X lacking 49 amino acids (Fig. 1C). Sequen-
cing of CHMP2B cDNA, derived by RT–PCR amplification
of mRNA extracted from lymphoblasts of the index patient,
confirmed the presence of the mutant transcript at apparently
equal amounts as the wild-type transcript. The latter indicated
Figure 3. CHMP2B C-truncating mutations lead to aberrant endosomal struc-
tures. SK-N-SH cells transiently transfected with N-terminal c-myc-tagged
expression constructs encoding recombinant proteins c-Myc-CHMP2BWildtype,
c-Myc-CHMP2BIntron5 or c-Myc-CHMP2BQ165X. Twenty-four hours post-
transfection, cells were immunostained with anti-c-Myc antibody to visualize
recombinant CHMP2B proteins. c-Myc staining is shown in red and DAPI
staining in blue. (A) CHMP2BWildtype had predominantly diffuse staining.
(B–D) Cells overexpressing CHMP2BIntron5 (B) or CHMP2BQ165X (C and D)
showed large aberrant vesicular structures. For CHMP2BQ165, vesicular staining
appeared on a background of nuclear and no cytoplasmic staining (46% of trans-
fected cells) or with diffuse cytoplasmic and nuclear staining (32% of trans-
fected cells).
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that the mutant transcript escaped nonsense-mediated decay
(NMD) and that C-truncated protein is likely to be formed.
NMD is anmRNA surveillance system that degrades transcripts
containing premature stop codons to prevent the formation of
aberrant truncated proteins. For stop codons in the penultimate
exon of a gene (exon 5 for CHMP2B), NMD generally only
occurs when the mutation is located at a distance greater than
55 bp from the final exon junction (26). The Belgian
CHMP2B nonsense mutation is located at 39 bp from the
exons 5–6 junction (Fig. 1), and as expected escapes NMD.
Here we showed that overexpression of Belgian
CHMP2BQ165X in human neuroblastoma cells leads to accumu-
lation of mutant protein on enlarged vesicular structures in a
similar distribution as Danish CHMP2BIntron5. Initially, we
reported enlarged vesicular structures in CHMP2BIntron5
expressing PC12 cells (13), and this phenotype was very
recently observed in mouse cortical neurons overexpressing
CHMP2BIntron5 (27). The enlarged vesicles partially
co-localized with the late endosomal marker CD63, consistent
with the role of CHMP2B and the ESCRT-III complex in endo-
somal function. C-terminal truncation of CHMP2B disrupts its
strong charge distribution. Previous studies showed that the
acidic C-terminus of CHMP proteins functions as auto-
inhibitory domain through intramolecular interactions with
their basic N-terminal halves, thereby closing the protein and
hiding the membrane binding and polymerization properties
of the N-terminal half (19,20,28,29). Normally, CHMP proteins
shuttle between this default, closed inactive soluble state in the
cytosol and an open activated state, which permits them to poly-
merize into heteromeric ESCRT-III complexes on the endoso-
mal membrane. However, C-terminal truncation relieves the
inhibitory effect of the C-terminus, thereby forcing the proteins
into a constitutively active state. This causes the truncated pro-
teins to remain bound in ESCRT-III complexes that accumulate
on the endosomal membrane. Moreover, CHMP proteins inter-
act with the VPS4 AAA-ATPase through sequences on their
C-terminus (19,30). As such, C-terminal truncation would
prevent binding with VPS4, which is mandatory for active dis-
sociation of the complex. Therefore, C-terminal truncation of
CHMP2B would be predicted to block MVB formation as the
mutant, constitutively active proteins can no longer dissociate,
thereby preventing the invagination process and intraluminal
vesicle formation. In support of this hypothesis, there is evi-
dence that C-terminal truncations of ESCRT-III proteins can
functionally affect endosomal pathways. Two independent
studies have shown that C-terminal truncations in CHMP2A
(19), CHMP2B (20) and other CHMP proteins (19,20) inhibited
virus budding, a process for which the ESCRT complexes are
required.
Together, these findings suggest that CHMP2B pathogen-
esis results from the production of C-truncated proteins that
in turn impair endosomal functioning. However, this is in
Figure 4. Aberrant endosomal structures caused by CHMP2B C-truncating mutants co-localize with late endosomal marker. Twenty-four hours post-transfection,
SK-N-SH cells were double-stained with anti-c-Myc antibody in red (A, D andG) and anti-CD63 antibody in green (B, E andH). DAPI stain in blue. The images
were merged to asses co-localization (C, F and I). CD63 showed partial co-localization with the CHMP2B positive vesicular structures.
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contrast to the recent finding of a CHMP2B C-truncating
mutation p.Arg186X in two apparently healthy at-risk individ-
uals from an Afrikaner FTLD family (24). The mutation was
excluded in their affected father, as well as in five of his dis-
eased relatives. Segregation analysis indicated that the two
unaffected children had inherited p.Arg186X from their
mother who had died at the age of 69 without signs of
memory or neurological impairments. The Afrikaner
C-truncation is smaller than that in CHMP2BIntron5 and
CHMP2BQ165X, but preliminary functional analysis showed
that overexpression of this truncated protein also leads to an
enlarged endosomal phenotype (Supplementary Material,
Fig. S3).
These contradictory data call for cautious interpretation of
the current genetic and in vitro functional data. If our data
are correct and C-truncated CHMP2B mutations are patho-
genic by impairing endosomal functioning, we would have
to assume that in the Afrikaner family the mother died
before onset of disease and that both middle-aged mutation
carriers might still develop the disease at a later age. This is
not impossible given that FTLD is characterized by a very
wide onset range, also within families, pointing to onset-
modifying factors (2). Alternatively, our functional data are
misleading due to an overinterpretation of the cellular pheno-
type which is produced by non-physiological overexpression
of the C-truncated proteins, despite the evidence described
above that C-terminal truncations can have inhibitory effects
on ESCRT protein functions (19,20). Possibly a more specific
cellular assay will distinguish between the Afrikaner and the
Danish and Belgian mutations. Finally, since in the Belgian
FTLD family, we still lack conclusive segregation data
linking the CHMP2B nonsense mutation to the disease, we
cannot rule out that CHMP2B is not the FTD-3 gene and
that the aberrant cellular phenotype is unrelated to FTLD.
However, the absence of mutations in any of the other
known genes located in the FTD-3 locus (25) supports the
notion that CHMP2B is the causative gene, unless the
disease mutation resides in an as yet uncharacterized gene in
the FTD-3 candidate region. Also, a mutation in a regulatory
region or a copy number variation remains possible, as these
types of mutations would not have been detected by the
screening methods used.
The second mutation we observed was a missense mutation,
p.Asn143Ser, in a patient with clinical diagnosis of CBD and
first symptoms around the age of 73. At least one other relative
was reportedly demented. The p.Asn143Ser mutation was
transmitted to an at-risk individual; however, this person’s
age was far below the onset age of the index patient. Also
in this family, we had no autopsy data available nor did we
have samples of patients in previous generations.
p.Asn143Ser changes a highly conserved residue located in
the Snf7 domain (residues 16–178) as well as the C-terminal
coiled-coil domain (residues 120–150) of the protein.
Protein–protein interaction studies in yeast have shown that
Vps4 binds to ESCRT-III through coiled-coil interactions
with the Vps2–Vps24 subcomplex (18). Hence,
p.Asn143Ser could perturb normal coiled-coil interactions
with Vps4 or another protein of the complex. Moreover,
p.Asn143Ser was absent in 918 control chromosomes (minor
allele frequency ,0.1%) adding to the evidence in favour of
a pathogenic nature for this missense mutation. The previously
identified p.Asp148Tyr (13) affects the same conserved
domains. In addition, the acidic Asp-residue is substituted by
a hydrophobic residue, which could in turn affect the charge
distribution of the protein. Overexpression of the missense
mutant p.Asp148Tyr did not lead to an enlarged endosomal
phenotype (Urwin and Isaacs, unpublished data), suggesting
that the missense mutations, if pathogenic, may have a more
subtle cellular phenotype. It is certainly plausible that endo-
some function could be impaired without formation of large
aberrant endosomes. This would be consistent with a recent
study that identified missense mutations in CHMP4B in
families with autosomal dominant cataracts (31). Overexpres-
sion of the missense mutations did not give a cellular pheno-
type, whereas a truncated form of CHMP4B did lead to
enlarged endosomes, and expressing the missense mutations
within a truncated CHMP4B protein led to a more severe
phenotype.
In conclusion, we identified another potential pathogenic
mutation in CHMP2B in a familial FTLD patient. Of interest
is that this nonsense mutation, as the original Danish
CHMP2B mutations, leads to a C-truncated protein because
it occurs in the 30 end of the penultimate exon 5 and therefore
escapes NMD. Both the Danish and Belgian C-truncated
mutations affect endosomal functioning in an in vitro overex-
pression cellular assay, supportive for a role for CHMP2B in
the neurodegenerative process of FTLD. However, we
should remain cautious in our interpretation of the genetic
and functional data as long as we have not been able to trans-
late the in vitro data to human or to an in vivo model such as
transgenic mice. Nevertheless, it remains intriguing that the
few CHMP2B nonsense and frameshift mutations producing
premature stop codons are all found in the 30 part of the
gene and escape NMD leading to stable transcripts coding
for potential pathogenic C-truncating CHMP2B proteins.
This could argue against a chance finding of these mutations
in familial FTLD patients since several examples are known
of such mutations leading to neurological diseases or to a
different clinical outcome (32).
Further, we showed that CHMP2B mutations could be
involved in a broader spectrum of neurodegenerative disease
including CBD. To date, a significant fraction of familial
FTLD cannot yet be explained by mutations in the currently
known FTLD genes, indicating that other genetic factors
must be involved in the aetiology of this disease. Considering
the molecular pathology of CHMP2B in FTLD, and the
similar phenotypes that are observed in vitro with other
members of the CHMP family, CHMP genes in general
might be good functional candidate genes for FTLD as well
as other neurodegenerative disorders.
MATERIALS AND METHODS
Patients and control individuals
Patients included in this study were derived from a prospective
Belgian study of neurodegenerative and vascular dementia
(33) and from a collection of demented patients referred
to our Molecular Diagnostic Unit for genetic testing.
Patients were diagnosed using a standard protocol including
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neurological examination, biochemical analyses, psychologi-
cal evaluation using the MMSE test, and neuroimaging
using CT and/or SPECT scan. Clinical diagnoses were based
on established clinical criteria (1,33–35).
Patients and relatives were contacted by research nurses
who gathered information on family history of dementia. Rela-
tives of the index patient were asked to participate in a genetic
study. Four hundred and fifty-nine neurologically healthy
Belgian control individuals were analysed for identified
CHMP2B mutations. All participants gave written informed
consent. The research protocols for this study were approved
by the Medical Ethical Committees of the Middelheim
General Hospital and the University of Antwerp. Descriptives
of the Belgian patients and control individuals are summarized
in Table 1.
Sequencing analysis
CHMP2B mutation analysis was performed in 146 patients.
Blood samples were collected for DNA extraction and the
establishment of lymphoblast cell lines according to standard
procedures. All CHMP2B exons and flanking intronic
regions were PCR amplified on genomic DNA (20 ng). Ampli-
fication products were purified with 1 U antarctic phosphatase
(New England Biolabs, Ipswich, MA, USA) and 1 U exonu-
clease I (New England Biolabs) and sequenced in both direc-
tions using the BigDye Terminator Cycle Sequencing kit v3.1
(Applied Biosystems, Foster City, CA, USA) on an ABI3730
automated sequencer (Applied Biosystems). Sequences were
analysed using the Software Package NovoSNP (36). In
patients, DR70.1 and DR157.1, carrying a CHMP2B mutation,
mutations in other FTLD related genes—MAPT, PGRN,
PSEN1 and VCP—had previously been excluded (11,37,38).
Mutations observed in index patients were analysed in
available DNA samples of relatives from DR157.1 and
DR70.1 and were excluded in control individuals by pyrose-
quencing. PCR amplification was performed as mentioned
above. Sequencing reactions were performed on a PSQTM
HS 96A Pyrosequenser (Biotage, Uppsala, Sweden, http://
www.biotage.com/). PCR and sequencing primers are listed
in Supplementary Material, Table S1.
Segregation analysis
Haplotype segregation analysis was performed in family
DR157. In addition to the index patient, DNA samples of
four at-risk individuals were obtained. Nine microsatellite
markers in the proximity of CHMP2B were genotyped in the
five family members. Genomic DNA (20 ng) was PCR ampli-
fied in three multiplex reactions. Fluorescently labelled pro-
ducts were resolved on an ABI3730 automated sequencer
(Applied Biosystems). Genotypes were assigned using
in-house developed genotyping software.
Transcript analysis
To test whether mutant CHMP2B transcripts were expressed,
RT-PCR analysis on mRNA isolated from Epstein–Barr virus-
transformed lymphoblasts of patient DR157.1 carrying
c.493C.T and of an asymptomatic at-risk individual in
family DR70, carrying c.428A.G. Total RNA was isolated
using the RiboPureTM Kit (Ambion, Applied Biosystems
Business, Austin, TX, USA). First-strand cDNA was syn-
thesized starting from total RNA with random hexamer
primers using the SuperScript III First-Strand Synthesis
System for RT–PCR kit (Invitrogen, Carlsbad, CA, USA).
cDNA primers were positioned in exons 3 and 6. RT–PCR
products were analysed on a 2% agarose gel and sequenced.
Primer sequences are listed in Supplementary Material,
Table S1.
Overexpression of CHMP2B in SK-N-SH cells
The c-myc-tagged p.Gln165X expression construct was gener-
ated using the QuikChange Site Directed Mutagenesis kit
(Stratagene) to introduce a stop codon at the appropriate pos-
ition into our c-myc-tagged CHMP2BWildtype construct that
has been previously described (13). The change was confirmed
by sequencing. All expression constructs were in the pLNCX2
mammalian expression vector (Clontech). SK-N-SH cells
were maintained in DMEM (Sigma-Aldrich) supplemented
with 10% heat inactivated fetal bovine serum (Invitrogen),
glutamine and sodium pyruvate. Transfections were performed
with Lipofecatime 2000 (Invitrogen). Anti-c-Myc antibody
(Abcam, catalogue number ab9106) was used at 1:800 for
immunofluorescence and anti-CD63 (University of Iowa
Developmental Hybridoma Bank, catalogue number H5C6)
was used at 1:400. Cell counts were performed by an investi-
gator blind to the treatment condition. A minimum of 100 cells
were counted for each expression construct and the average
taken of three independent experiments. Images were obtained
using either an Axioplan 2 MOT fluorescence microscope
(Zeiss) or an LSM510 META confocal microscope (Zeiss).
Table 1. Descriptives of Belgian patients and control individuals
Individuals Mean AAO/
AAI+STDV
(range)
Positive
family history
(%)
Male/
female
FTLD patients 134 63.51+9.23
(40–90)
54 (40%) 71/63
FTLD
unspecified
46
FTLD, FTD 63
FTLD,
PNFA
9
FTLD, SD 2
FTD-ALS 9
FTDP 5
CBD patients 7 65.00+9.92
(48–73)
3 (43%) 1/6
PSP patients 5 69.00+4.53
(62–73)
1 (20%) 2/3
Control
individuals
459 58.6+16.0
(19–92)
— 207/253
AAO, age at onset in years is given for patients, AAI, age at inclusion in years
for control individuals; STDV, standard deviation; FTLD, frontotemporal
lobar degeneration; FTD, frontotemporal dementia; FTD-ALS, FTD with
amyotrophic lateral sclerosis; FTDP, FTD with parkinsonism. A positive
family history was defined as having at least one first-degree relative with
dementia.
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SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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